General

EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma. Tzogani K et al. Oncologist. 2018 Jan 25. pii: theoncologist.2017-0328. doi: 10.1634/theoncologist.2017-0328. [Epub ahead of print]. Immunopathogenesis and immunotherapy of multiple myeloma. Tamura H et al. Int J Hematol. 2018 Jan 24. doi: 10.1007/s12185-018-2405-7. [Epub ahead of print]. Survival of ethnic and racial minority patients with multiple myelomatreated with newer medications.…

Diagnostic techniques and prognostic indicators

Prognostic Value of IL-10 and Its Relationship with Disease Stage in Iranian Patients with Multiple Myeloma. Shekarriz R et al.Asian Pac J Cancer Prev. 2018 Jan 27;19(1):27-32. Discriminating Depth of Response to Therapy in Multiple Myeloma Using Whole-body Diffusion-weighted MRI with Apparent Diffusion Coefficient: Preliminary Results From a Single-center Study. Wu C et al. Acad Radiol. 2018 Jan 16. pii: S1076-6332(17)30518-4. doi: 10.1016/j.acra.2017.12.008.…

Current treatments

Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. Dhakal B et al. JAMA Oncol. 2018 Jan 4. doi: 10.1001/jamaoncol.2017.4600. [Epub ahead of print]. Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. Gertz MA et al. Mayo Clin Proc. 2018 Jan;93(1):56-58. doi: 10.1016/j.mayocp.2017.09.012. Prolonged survival after second autologous transplantation and lenalidomide maintenance…

Complications of myeloma and its treatments

Hemostatic Abnormalities in Multiple Myeloma Patients. Gogia A et al. Asian Pac J Cancer Prev. 2018 Jan 27;19(1):127-130. Incidence of Second Primary Malignancies after Autologous Transplantion for Multiple Myeloma in the Era of Novel Agents. Sahebi F et al. Biol Blood Marrow Transplant. 2018 Jan 12. pii: S1083-8791(18)30021-1. doi: 10.1016/j.bbmt.2018.01.006. [Epub ahead of print]. Chemotherapy-induced Nausea and Vomiting Prophylaxis in High-dose Melphalan and Autologous Stem…

Results from TEAMM clinical trial reported

Results from the Phase III TEAMM (Tackling EArly Morbidity and Mortality in Myeloma) trial have recently been reported at the American Society of Haematology 2017 conference. This study assessed the benefit of levofloxacin antibiotic prophylaxis and its effect on healthcare associated infections in newly diagnosed myeloma patients. The results show that levofloxacin prophylaxis had a…

Carfilzomib treatment associated with cardiovascular events in myeloma patients

A meta-analysis conducted by researchers at the University of Pennsylvania has shown that treatment with carfilzomib (Kyprolis®) is associated with a higher incidence of cardiovascular events in myeloma patients. The study found that 18.1% of myeloma patients receiving carfilzomib experienced cardiovascular events, including hypertension, cardiac arrest, cardiac failure and arrhythmias, compared to only 3.8% of…

Supportive treatments

Mobilization of Hematopoietic Progenitor Cells with Standard or Reduced Dose Filgrastim after Vinorelbine in Multiple Myeloma Patients. a Randomized Prospective Single Center Phase II Study. Samaras P et al. Biol Blood Marrow Transplant. 2017 Dec 12. pii: S1083-8791(17)31679-8. doi: 10.1016/j.bbmt.2017.12.775. [Epub ahead of print]. Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network.…

General

Falls in Older Adults with Multiple Myeloma. Wildes TM et al. Eur J Haematol. 2017 Dec 14. doi: 10.1111/ejh.13009. [Epub ahead of print]. BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations From the Organizing Committee. Holstein SA et al. Biol Blood Marrow Transplant. 2017 Dec 11. pii: S1083-8791(17)31678-6. doi: 10.1016/j.bbmt.2017.12.774. [Epub ahead of print]. Multiple Myeloma and Bone:…

Current treatments

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. Mateos MV et al. N Engl J Med. 2017 Dec 12. doi: 10.1056/NEJMoa1714678. [Epub ahead of print]. Melphalan 140mg/m2 or 200mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party. Auner HW et al. Haematologica. 2017…